Guardiola J, Xiol X, Escribá J M, Castellví J M, Castellote J, Baliellas C, Rafecas A, Casais L A
Service of Gastroenterology and General Surgery, Hospital de Bellvitge Princeps d'Espanya, Spain.
Am J Gastroenterol. 1995 Dec;90(12):2097-102.
The role of peritoneovenous shunt in the management of refractory ascites has not been clearly established. The aim of this study was to determine readily accessible predictive survival factors in cirrhotic patients with refractory ascites treated with a peritoneovenous shunt.
We studied a cohort of 100 cirrhotic patients with refractory ascites who underwent peritoneovenous-shunt placement in a university-based reference hospital.
The estimated median survival of patients after shunt placement was 11 months (95% CI, 7-14 months). Multivariate analysis based on the proportional hazards model disclosed four independent variables associated with poor survival: high Pugh score, nonalcoholic etiology, low ascitic fluid protein concentration, and history of spontaneous bacterial peritonitis.
Mortality of cirrhotic patients treated with a peritoneovenous shunt can be determined by a prognostic index using four easily available variables. Such a prognostic index, once prospectively validated, could be used as an adjunct in planning treatment of cirrhotic patients with refractory ascites.
腹腔静脉分流术在难治性腹水治疗中的作用尚未明确确立。本研究的目的是确定接受腹腔静脉分流术治疗的肝硬化难治性腹水患者易于获得的预测生存因素。
我们研究了一组100例在一所大学附属医院接受腹腔静脉分流术的肝硬化难治性腹水患者。
分流术后患者的估计中位生存期为11个月(95%可信区间,7 - 14个月)。基于比例风险模型的多变量分析揭示了与生存不良相关的四个独立变量:高Pugh评分、非酒精性病因、腹水蛋白浓度低和自发性细菌性腹膜炎病史。
使用四个易于获得的变量的预后指数可以确定接受腹腔静脉分流术治疗的肝硬化患者的死亡率。这样一个预后指数一旦经过前瞻性验证,可作为规划肝硬化难治性腹水患者治疗的辅助手段。